Add time:08/16/2019         Source:sciencedirect.com

BackgroundTacrolimus (Tac), an essential component of immunosuppressive therapy after solid-organ transplantation, has a narrow therapeutic index and requires therapeutic drug monitoring. Monitoring of Tac predose blood concentrations seems to be not always sufficient to avoid adverse effects. The aim of the study was to evaluate the levels of main Tac metabolites, 13-O-demethyl tacrolimus (13-DMT), 31-O-demethyl tacrolimus (31-DMT), and 15-O-demethyl tacrolimus (15-DMT), in kidney transplant recipients and to link them to clinical and biochemical parameters.

We also recommend Trading Suppliers and Manufacturers of Demethyl (cas 11041-94-4). Pls Click Website Link as below: cas 11041-94-4 suppliers